Exemestane
About
Therapy type: Hormone therapy
Therapy strategy: Aromatase inhibition
Mappings
NCI Thesaurus: Exemestane (ncit:C1097)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| EMA (1) FDA (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Everolimus, Exemestane | |
| HSE (1) | ER positive, PR positive | Invasive Breast Carcinoma | Exemestane | |
| HPRA (1) HSE (1) | ER positive | Invasive Breast Carcinoma | Exemestane | |
| HSE (1) | PR positive | Invasive Breast Carcinoma | Exemestane | |
| EMA (1) FDA (1) HSE (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Exemestane | |
| EMA (1) FDA (1) HSE (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Abemaciclib, Exemestane | |
| EMA (1) FDA (1) HSE (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Exemestane |